Akebia Recalls Auryxia Tablets Due to Manufacturing Deviations
Akebia Therapeutics is voluntarily recalling 2,170 bottles of Auryxia (ferric citrate) tablets due to CGMP deviations. The FDA classified this as a Class II recall.
- Product
- AURYXIA — AURYXIA (FERRIC CITRATE)
- Category
- Drug
- Distribution
- Distributed nationwide